Related Experiment Video

Updated: Jul 31, 2025

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

242

Enalapril attenuated CFA provoked arthritic manifestation by modulating proinflammatory and anti-inflammatory

Yusra Habib Khan1, Sumera Qasim2, Ambreen Malik Uttra3

  • 1Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Saudi Arabia.

Life Sciences
|May 5, 2023
PubMed

Insights

Enalapril shows significant anti-arthritic effects by reducing inflammation and joint damage in a rat model. Further research is needed to fully understand its mechanism of action in treating arthritis.

Area of Science:

  • Pharmacology
  • Immunology
  • Rheumatology

Background:

  • Enalapril, an angiotensin-converting enzyme inhibitor, possesses documented anti-inflammatory properties.
  • Arthritis is a debilitating inflammatory condition affecting joints, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the anti-arthritic efficacy of enalapril.
  • To explore the potential of enalapril as a treatment for arthritis.

Main Methods:

  • An arthritis model was induced using Complete Freund's Adjuvant (CFA) in rats.
  • Evaluated parameters included paw volume, body weight, arthritic index, hematological and biochemical markers, cytokine levels, and radiographic analysis.

Main Results:

  • Enalapril significantly reduced paw volume and arthritic index (p˂0.001), while preserving body weight.
  • Normalized hematological and biochemical alterations, suppressed pro-inflammatory cytokines, and elevated anti-inflammatory cytokines.
  • Radiographic and histopathological analyses confirmed enalapril's protective effect on joint architecture.

Conclusions:

  • Enalapril exhibits notable anti-arthritic activity.
  • The findings suggest enalapril's potential in managing arthritis, though detailed mechanistic studies are warranted.
Keywords:
Anti-inflammatory cytokinesArthritisCFAEnalaprilProinflammatory cytokines

More Related Videos

Development of Recombinant Proteins to Treat Chronic Pain10:37

Development of Recombinant Proteins to Treat Chronic Pain

Published on: April 11, 2018

9.6K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.6K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
474
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
794
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
379
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
716
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K